Physician profile
James Aram
NPI 1417954058
$1,799.04
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $475 · 2021: $659 · 2022: $288.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $362.83 | 2019-2022 | |
| Novo Nordisk INC | $314.66 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.63 | 2019-2022 | |
| Lilly USA, LLC | $190.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $172.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $123.68 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $115.19 | 2019-2021 | |
| Boston Scientific Corporation | $79.10 | 2021 | |
| Abbvie INC. | $65.77 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.01 | 2021-2022 | |
| Mannkind Corporation | $26.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.77 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.50 | 2019 | |
| Sanofi Pasteur INC. | $16.27 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.89 | 2020 | |
| Amgen INC. | $13.60 | 2019 | |
| Abbott Laboratories | $13.11 | 2021 | |
| Horizon Therapeutics Plc | $11.21 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Aram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.